You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

market mover

Vivus shares surge as FDA approves weight-loss drug

Consumers can soon choose between Vivus’s new drug and Belviq, from Arena Pharmaceuticals and Eisai Co. The pills are the first approved for obesity since 1999.

jewel samad/AFP/Getty Images/File 2011

Consumers can soon choose between Vivus’s new drug and Belviq, from Arena Pharmaceuticals and Eisai Co. The pills are the first approved for obesity since 1999.

Continue reading below

Vivus Inc. rose the most in
almost four months after winning approval from US regulators for its obesity drug, Qsymia. Vivus plans to begin selling Qsymia in the fourth quarter, with a warning about potential heart and birth-defect risks. It may generate $1.2 billion in sales in 2016, according to the average of five analysts’ estimates.

Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.